Canadian Health&Care Mall: Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors
Read more http://bloghealthcaremall.com/canadian-healthcare-mall-pulmonary-complications-of-novel-antineoplastic-agents-for-solid-tumors.html
Canadian Health&Care Mall: Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors
Gefitinib Gefitinib is an oral EGFR tyrosine kinase inhibitor that is active against NSCLC, and ovarian, colon, head and neck, and breast cancers. Gefitinib-induced lung toxicity usually occurs within the first 90 days of treatment with gefitinib. Interstitial pneumonitis, diffuse alveolar...















